3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
23
fludarabine
14
Rituximab
14
Specimen Handling
8
Magnetic Resonance Spectroscopy
7
Doxorubicin
7
pirtobrutinib
6
Vincristine
6
Prednisone
6
zanubrutinib
4
polatuzumab vedotin
4
obinutuzumab
4
Nivolumab
4
Etoposide
4
Dexamethasone
4
Biopsy
4
tazemetostat
3
tafasitamab
3
pembrolizumab
3
ibrutinib
3
glofitamab
3
fludarabine phosphate
3
acalabrutinib
3
Immunotherapy, Adoptive
3
Bendamustine Hydrochloride
3
venetoclax
2
pomalidomide
2
etoposide phosphate
2
cemiplimab
2
Prednisolone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Inosine Monophosphate
×
90 days
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled